Wei Zhong
Chief Executive Officer Wayshine Biopharm
Seminars
Wednesday 28th January 2026
Validating DNA-PK Inhibition as a Radiosensitizer to Overcome Past Challenges & Advance into the Clinic
1:45 pm
• Reviewing lessons learned from past DNA-PK inhibitor programs and how improved potency, PK, and selectivity address prior limitations
• See how Wayshine Pharma is advancing WN-C001 to enhance radiotherapy efficacy with a favorable safety profile
• Highlighting translational insights and the development path toward clinical validation of DNA-PK inhibition as a radio-sensitization strategy
